An NIH-funded study found that semaglutide treatment extended median lifespan and improved several measures of function in older female mice.
Researchers reported better muscle and cognitive performance and signs of reduced age-related inflammation. In one experiment, median lifespan was nearly 100 days longer in treated mice than in untreated controls.
The findings are preclinical. NIH emphasized that they do not show the same effect would occur in people and that human studies would be needed before drawing conclusions about longevity.